(Q42947260)

11 November 2017

title

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels (English)

1 reference

11 November 2017

main subject

peginterferon alfa-2a

1 reference

1 reference

1 reference

2

1 reference

11 November 2017

3

Yilmaz Cakaloglu

1 reference

11 November 2017

1

Vincent Rijckborst

1 reference

11 November 2017

Martijn J ter Borg

13

0 references

Krzysztof Simon

object named as

Krzysztof Simon

7

0 references

Robert Flisiak

object named as

Robert Flisiak

9

0 references

author name string

Peter Ferenci

4

1 reference

11 November 2017

Fehmi Tabak

5

1 reference

11 November 2017

Meral Akdogan

6

1 reference

11 November 2017

Ulus S Akarca

8

1 reference

11 November 2017

Elke Verhey

10

1 reference

11 November 2017

Anneke J Van Vuuren

11

1 reference

11 November 2017

Charles A B Boucher

12

1 reference

11 November 2017

Harry L A Janssen

14

1 reference

11 November 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

volume

52

1 reference

11 November 2017

issue

2

1 reference

11 November 2017

page(s)

454-461

1 reference

Hepatitis B Virus Infection

11 November 2017

cites work

1 reference

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

21 January 2018

1 reference

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

21 January 2018

1 reference

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

21 January 2018

1 reference

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay

21 January 2018

1 reference

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

Methods for categorizing a prognostic variable in a multivariable setting

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

Treatment predictors of a sustained virologic response in hepatitis B and C.

21 January 2018

1 reference

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

Actions of cytokines on the immune response and viral interactions: an overview

21 January 2018

1 reference

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

21 January 2018

1 reference

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.23722

1 reference

release_zwewexi2tbbzteffhwi3gud5p4

11 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zwewexi2tbbzteffhwi3gud5p4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference